Date | Price Target | Rating | Analyst |
---|---|---|---|
10/1/2024 | $25.00 | Outperform | Wedbush |
9/25/2024 | $21.00 | Buy | Truist |
7/25/2024 | $24.00 | Buy | BofA Securities |
5/9/2024 | Overweight | Cantor Fitzgerald |
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
Wedbush initiated coverage of Perspective Therapeutics with a rating of Outperform and set a new price target of $25.00
Truist initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $21.00
BofA Securities initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $24.00
B of A Securities analyst Alec Stranahan initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and announces Price Target of $24.
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM"), which is being held in Hamburg, Germany, from October 19-23, 2024. Presentations regarding certain of the Company's other assets, including results based on investigator-initiated use of certain of those assets, will also be made at EANM. Descriptions of these presentations are provided in the tab
SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the "FDA") granted Fast Track Designation for the development of 212Pb VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma and who have demonstrated MC1R tumor expression. Melanocortin 1 receptor, or "MC1R," is a protein that can be overexpressed in metastatic melanoma. The FDA's Fast Track Designation is one of several approaches utilized by the FDA to exp
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. Morgan Stanley 22nd Annual Global Healthcare ConferenceDate: September 6, 2024Location: New York, NYFormat: Fireside ChatTime: 9:15 a.m. – 9:50 a.m. ET 2024 Cantor Global Healthcare ConferenceDate: September 17, 2024Location: New York, NYFormat: Fireside ChatTime: 10:55 a.m. – 1
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
First Quarter 2024 Worldwide revenue of $370.0 million, an increase of 23.0% from first quarter 2023 GAAP fully diluted net income per share of $1.87, compared to GAAP fully diluted net loss per share of $0.04 in first quarter 2023. Adjusted fully diluted net income per share of $1.69 compared to adjusted fully diluted net income per share of $1.47 in the first quarter 2023The Company increases full year 2024 net revenue and earnings guidance and provides guidance for the second quarter 2024 BEDFORD, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fig
SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the consummation of the acquisition of a state-of-the-art manufacturing facility and associated equipment and systems for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. Previously operated by Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company, this 11,500 square foot facility, located in Somerset, New Jersey, has operated in compliance with both Part 212 and Part 211 of Ti
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membership list, considered to be final, as of Monday, June 10th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total mark
Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023.First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma. RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period end
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13D/A - Perspective Therapeutics, Inc. (0000728387) (Subject)